<DOC>
	<DOC>NCT00632424</DOC>
	<brief_summary>This Phase 1 study of oral ixabepilone given every 6 hours for 3 doses on Day 1, every 21 days, was a dose-finding study designed to determine the maximum tolerated dose (MTD) and safety of this dosing schedule in participants with advanced cancer</brief_summary>
	<brief_title>Phase 1 Trial of Oral Ixabepilone</brief_title>
	<detailed_description />
	<mesh_term>Epothilones</mesh_term>
	<criteria>Males and females, 18 or older Histologically or cytologically confirmed diagnosis of solid tumor malignancy Measurable or nonmeasurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria Karnofsky Performance Status (KPS) of 70100 Recovered from toxicities resulting from previous therapies More than 3 prior cytotoxic regimens in the metastatic setting Current or recent gastrointestinal (GI) disease that would impact the absorption of study drug Inability to swallow whole capsules Inadequate hepatic and renal function Function exposure to any epothilone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>